OC
OCD1.F ChromaDex Corporation
- Market cap
- EUR 149M
- P/E
- 18.8x
- P/B
- 2.00x
- ROE
- 9.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OCD1.F undervalued?
Graham numberOCD1.F trades 29.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ChromaDex Corporation fundamental analysis
No fundamental analysis for ChromaDex Corporation yet.
ChromaDex Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ChromaDex Corporation
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingred…
Full company profileChromaDex Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ChromaDex Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 26.8M | 21.2M | 31.6M | 46.3M | 59.3M | 67.4M | 72.1M | 83.6M | 99.6M | 129M | 118M |
| Gross Profit | 11.9M | 10.5M | 16.1M | 25.8M | 35.3M | 41.5M | 42.8M | 50.8M | 61.6M | 83.2M | 75.2M |
| Operating Income | -2.25M | -16.4M | -33.2M | -31.3M | -19.9M | -27.1M | -18.6M | -5.60M | 7.73M | 14.3M | 919K |
| EBITDA | - | -15.7M | -32.3M | -29.8M | -18.3M | -25.4M | -16.7M | -3.89M | 9.21M | 15.7M | 2.79M |
| Net Income | -2.93M | -11.4M | -33.3M | -32.1M | -19.9M | -27.1M | -16.5M | -4.94M | 8.55M | 17.4M | 8.14M |
| EPS | - | -0.21 | -0.60 | -0.54 | -0.32 | -0.40 | -0.22 | -0.07 | 0.11 | 0.22 | 0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 19.8M | 62.7M | 42.2M | 40.2M | 38.4M | 57.8M | 54.1M | 55.0M | 68.3M | 106M | 109M |
| Total Liabilities | 9.78M | 8.89M | 15.1M | 19.8M | 21.9M | 26.1M | 25.4M | 26.5M | 22.2M | 29.9M | 25.6M |
| Shareholders' Equity | 9.97M | 53.8M | 27.2M | 20.4M | 16.4M | 31.7M | 28.7M | 28.5M | 46.1M | 76.5M | 83.1M |
| Cash & Short-term Investments | 1.64M | 45.4M | 22.4M | 18.6M | 16.5M | 28.0M | 20.2M | 27.2M | 44.5M | 64.6M | 69.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.94M | -9.80M | -20.9M | -20.4M | -10.6M | -24.2M | -15.1M | 7.12M | 12.1M | 13.5M | 5.60M |
| Capital Expenditure | 1.72M | 1.17M | 1.32M | 743K | 124K | 409K | 334K | 148K | 163K | 292K | 269K |
| Free Cash Flow | - | -11.2M | -22.4M | -21.2M | -10.7M | -24.6M | -15.4M | 6.97M | 11.9M | 13.2M | 5.33M |
| Ratios | |||||||||||
| ROE | -29.4% | -21.1% | -122.6% | -157.2% | -121.3% | -85.5% | -57.7% | -17.4% | 18.5% | 22.7% | 9.8% |
| ROA | -14.8% | -18.1% | -78.9% | -79.9% | -51.9% | -46.9% | -30.6% | -9.0% | 12.5% | 16.3% | 7.5% |
| Net Profit Margin | -10.9% | -53.7% | -105.6% | -69.4% | -33.6% | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% | 6.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ChromaDex Corporation dividends
ChromaDex Corporation has not paid dividends in the last 9 fiscal years.
Who owns ChromaDex Corporation
- Insiders 29.43%
- Institutions 41.09%
- Public & others 29.49%
- Shares outstanding 79.2M
- Free float 59.1M
ChromaDex Corporation company profile
- Company name
- ChromaDex Corporation
- Ticker
- OCD1.F
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Biotechnology
- Employees
- 117
- Fiscal year end
- December
- Address
- 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024
- Phone
- 310 388 6706
- Website
- niagenbioscience.com
About ChromaDex Corporation
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
ChromaDex Corporation management
10- Mr. Frank Louis Jaksch Jr.Co-Founder & Chairman · born 1968
- Mr. Robert N. FriedCEO & Director · born 1960
- Mr. Ozan Pamir C.F.A.CFO & Principal Accounting Officer · born 1992
- Mr. Carlos LopezSenior VP & General Counsel · born 1981
- Dr. Andrew Shao Ph.D.Senior Vice President of Global Regulatory & Scientific Affairs
- Ms. Michiko KelleyChief Marketing Officer
- Ms. Chu YanManaging Director of Asia Pacific
- Kendall KnyschHead of Media Relations & Partnerships
- Mr. James LeeController · born 1976
- Wesley YuVice President of Finance